ECI®: What to Expect During the T Cell Infusion

The ELIAS Cancer Immunotherapy (ECI®) is an alternative treatment option to chemotherapy for certain types of canine cancer. ECI is a two-step sequential and interdependent protocol. Step 1 involves priming the patient’s immune system with a personalized vaccine that stimulates an immune response. Step 2 is the activation, expansion and reinfusion of the patient’s cancer antigen-specific T cells which can travel to and attack the cancer cells in the dog’s body. We’re often asked if patients can receive only the vaccines, without T cell infusion. Both steps are essential and play different roles in treatment. Stimulating the immune system isn’t enough to eliminate cancer. The vaccine step primes the immune system to create T cells that can specifically recognize the cancer cells. In the second step of the treatment protocol, these T cells are collected from the blood, and then functionally activated and numerically expanded in the laboratory. Once [...]

By |2022-11-17T19:36:13-06:00November 16th, 2022|Blog|0 Comments

ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy

In vitro study of the ELIAS Cancer Immunotherapy (ECI®) showed personalized T cell immunotherapy initiated a significant immune response against target cancer cells. OLATHE, Kan., August 10, 2022 -- ELIAS Animal Health recently presented new mechanism of action data for the ELIAS Cancer Immunotherapy (ECI®) at the 2022 American College of Veterinary Internal Medicine Forum. ECI is an adoptive cell therapy that stimulates a patient’s immune system to recognize and attack cancers. ECI uses a personalized vaccine made from a patient’s own cancer cells to “prime” the immune cells to recognize the cancer. These primed immune cells—which are collected from the patient through a procedure called apheresis—are activated and expanded ex vivo for reinfusion into the patient, where they travel to the cancer cells and attack them. In vitro study demonstrates how vaccine-primed T cells mount an immune response against cancer cells [...]

By |2022-08-10T08:12:46-06:00August 10th, 2022|News, Press Releases|0 Comments

PODCAST: ELIAS CEO talks immunotherapy and canine osteosarcoma on Dog Cancer Answers

ELIAS Animal Health CEO, Tammie Wahaus, was a recent guest on the Dog Cancer Answers podcast to discuss how the ELIAS Cancer Immunotherapy (ECI) works, the role of a healthy immune system in successful immunotherapy, and why we chose to focus on canine osteosarcoma first. Listen to the episode below, or read the full transcript at Dog Cancer Answers online. Listen to more episodes of the Dog Cancer Answers podcast here.  

By |2022-10-20T13:12:00-06:00June 1st, 2022|Blog|0 Comments

PODCAST: ELIAS CEO Discusses Treatment Option for Bone Cancer in Dogs on Fuzzybutts & Friends

ELIAS Animal Health CEO, Tammie Wahaus, was the featured guest on the Fuzzybutts & Friends podcast. Hosted by Luke Robinson, founder of the PuppyUp Foundation, the podcast explores how the ELIAS Cancer Immunotherapy (ECI®) works against bone cancer in dogs, as well as how ELIAS is committed to developing more immunotherapies for pets with cancer. Check out the episode below!   Learn more about the PuppyUp Foundation here. Watch more episodes of the Fuzzybutts & Friends podcast here.  

By |2022-07-17T12:48:00-06:00April 29th, 2022|Blog|0 Comments

ELIAS Cancer Immunotherapy Gives Dogs with Osteosarcoma More Days at Home

Recent advancements in canine cancer treatment offer the potential for better outcomes, especially the advancements in immunotherapy treatments. A discussion of the ELIAS cancer immunotherapy (ECI®) for the treatment of canine osteosarcoma in Clinician's Brief pointed out that "ECI is the only 2-step immunotherapy in veterinary medicine that has the potential to match or exceed the current standard of care while reducing or eliminating the need for chemotherapy." The article, "Osteosarcoma Immunotherapy for More Days at Home," discusses the evidence-based science behind ECI, the potential benefits over chemotherapy, and how referring veterinarians play an active and vital role in the care continuum. Read the full article at Clinician's Brief online.

By |2022-03-16T17:51:21-06:00February 22nd, 2022|Blog|0 Comments

ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs

Ten sites now participating in trial of alternative treatment to chemotherapy for canine osteosarcoma Olathe, Kansas, Nov. 12, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces that 10 investigation sites across the U.S. are now participating in the pivotal trial of ELIAS cancer immunotherapy (ECI®). This marks an expansion of the study ELIAS initiated in May to pursue licensure of ECI treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. The geographical areas served by the clinical trial investigation sites include Southern California, the Intermountain Region, the Desert Southwest, the Chicago metropolitan area, North Texas, the Carolinas, and the Mid-Atlantic region, which includes Southeast Pennsylvania, Virginia and Washington D.C. ELIAS will continue recruiting sites to further expand pet owner access to the trial. To learn more about participating [...]

By |2022-01-08T14:27:21-06:00November 12th, 2020|News, Press Releases|0 Comments

Clinical study results demonstrate long term survival in dogs with osteosarcoma treated with ELIAS cancer immunotherapy

Results of a clinical study of the ELIAS cancer immunotherapy (ECI®) protocol demonstrated that the administration of an autologous cancer cell vaccination, adoptive T cell transfer, and interleukin‐2 resulted in long‐term survival for dogs with osteosarcoma, a deadly form of bone cancer. The article, published in the Journal of Veterinary Internal Medicine by researchers from the University of Missouri, describes the 14-dog single-arm prospective study and discusses the results. The objective of the study was to evaluate the hypothesis that dogs could be treated safely with the ECI protocol, which includes administration of ex vivo activated T cells, and experience survival times twice that of amputation alone. Median survival time for dogs in the study was 415 days, with one dog developing metastasis then experiencing spontaneous complete remission. Read the full study results. In May, ELIAS Animal Health announced the initiation of a follow-up study to pursue licensure of ECI [...]

By |2020-07-27T10:26:01-06:00July 14th, 2020|News|0 Comments

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. It will be a two-arm study with a 1:1 randomization comparing ECI and carboplatin, a type of chemotherapy. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment [...]

By |2020-06-16T10:15:26-06:00May 28th, 2020|News|0 Comments

ELIAS Animal Health Clinical Dataset Supports FDA Fast Track Designation for TVAX Biomedical

Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and we are pleased that the results of that study contributed to the FDA’s approval of the GBM Fast Track application. This is a significant accomplishment in that Fast Track Designation is not easily granted by the FDA and requires TVAX to provide evidence of its ability to successfully treat a [...]

By |2020-05-05T07:39:44-06:00May 5th, 2020|News|0 Comments
Go to Top